Proposed by the EPA section on Psychopharmacology -Psychopharmacology during Infections, including COVID-19 Infectious diseases are more frequent among people with psychiatric disorders as compared to the general population and they significantly contribute to the higher mortality rates observed in psychiatric disorders, e.g. schizophrenia, depression, bipolar disorders. Psychiatric residency training and continuing medical education for psychiatrists provide very limited or no information about the management of psychiatric patients with infectious diseases. The COVID-19 pandemic confronted the health care systems with enormous challenges, including the treatment of psychiatric patients suffering from coronavirus infection. The main objectives of this symposium are: 1. to provide data about the importance of infections for patients with psychiatric disorders; 2. to provide state of the art information about the management of patients with comorbid psychiatric disorders and infectious diseases; 3. to help integrating the lessons learned from COVID-19 pandemic into psychiatric practice. The following specific topics will be addressed: 1. The prevalence of comorbidity and mortality associated with infectious diseases in patients with psychiatric disorders (presenter: Istvan Bitter, Hungary); 2. The challenges of psychopharmacological treatment during the COVID-19 pandemic in Lombardy* (presenter: Antonio Vita, Italy); 3. The interactions between Covid-19 drugs and psychotropic agents (presenter: Christoph Hiemke, Germany); 4. The pharmacotherapy of infections in patients with mental disorders receiving psychotropic drugs: focus on good practices (presenter: Matej Stuhec, Slovenia). * Lombardy is one of the regions in the world hardest hit by the COVID-19 pandemic.